Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

View Our Latest Presentations

Access our latest presentations including a webcast of our presentation at the Bank of America Merrill Lynch Global Healthcare Conference 2014 on September 19 as well as scientific posters and presentations in our Download Library.

Envisioning the Future of Cancer Treatment: A Video with CEO Jan van de Winkel

Genmab's CEO shares his perspective on how the company's work to develop innovative antibody therapeutics could change the lives of cancer patients in the future.  Click here to watch the video.

Genmab Opens Doors to Innovation

Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on

Latest news


  • At the heart of Genmab is a deep desire to improve the quality of life for cancer patients.
  • Click here to watch our video about our fight against cancer.


Stock Price as of 10/21/2014 12:00 AM (CET)

  • Share Price DKK 240.00
  • Change (in DKK) 4.60
  • Volume 320464

Stock Information